Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Deloitte
Harvard Business School
McKinsey
Citi
Cerilliant
Covington
Queensland Health
Julphar

Generated: May 26, 2018

DrugPatentWatch Database Preview

Piramal Imaging Company Profile

« Back to Dashboard

What is the competitive landscape for PIRAMAL IMAGING, and when can generic versions of PIRAMAL IMAGING drugs launch?

PIRAMAL IMAGING has one approved drug.

There is one US patent protecting PIRAMAL IMAGING drugs.

There are thirty patent family members on PIRAMAL IMAGING drugs in twenty-five countries and fifteen supplementary protection certificates in twelve countries.

Summary for Piramal Imaging
International Patents:30
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Piramal Imaging

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Imaging NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes 7,807,135 ➤ Sign Up Y Y ➤ Sign Up
Piramal Imaging NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Piramal Imaging

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Sign Up
8,465,726 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Piramal Imaging Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015005 Lithuania ➤ Sign Up PRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2015 Austria ➤ Sign Up PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224
647 Luxembourg ➤ Sign Up PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
2015005,C2213652 Lithuania ➤ Sign Up PRODUCT NAME: FLORBETABENAS (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Julphar
Deloitte
Chinese Patent Office
Mallinckrodt
Express Scripts
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.